reviewAlzheimer s & Dementia Translational Research & Clinical InterventionsApr 1, 2024GOLD OA

Alzheimer's disease drug development pipeline: 2024

JLJeffrey L. CummingsYZYadi ZhouGLGaram LeeKZKate ZhongJRJorge Ramón Fonseca Cacho

University of Nevada, Las Vegas · Cleveland Clinic Lerner College of Medicine · +2 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

Abstract INTRODUCTION New therapies to prevent or delay the onset of symptoms, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed. METHODS We interrogated clinicaltrials.gov including all clinical trials assessing pharmaceutical therapies for AD active in on January 1, 2024. We used the Common Alzheimer's Disease Research Ontology (CADRO) to classify the targets of therapies in the pipeline. RESULTS There are 164 trials assessing 127 drugs across the 2024 AD pipeline. There were 48 trials in Phase 3 testing 32 drugs, 90 trials in Phase 2 assessing 81 drugs, and 26 trials in Phase 1 testing 25 agents. Of the 164 trials, 34% ( N = 56) assess disease‐modifying…

Citation impact

278
total citations
FWCI
82.64
Percentile
100%
References
19
Citations per year

Authors

6

Topics & keywords

Topics
Keywords
  • Drug development
  • Pipeline (software)
  • Disease
  • Drug
  • Medicine
  • Neuroscience
  • Intensive care medicine
  • Psychology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding